Background: Hepatocellular carcinoma (HCC) is the sixth greatest frequent disease in the world and the second biggest cause of cancer mortality in men in developing nations, with over 782,000 deaths globally each year, with China accounting for almost half of them.
Aim of the study: The goal of this research was to see whether epidermal growth factor might be used as an indicator for early detection of hepatocellular cancer.
Patients and methods: One hundred patients were selected from the Internal Medicine department's outpatient clinic and ward at Sayed Galal University Hospital for this case control research. The study's patients were placed into three groups: Group I : 40 patients with HCC, Group II : 40 cirrhotic patients without HCC, and Group III : 20 healthy people who were devoid of hepatic diseases stigmata.
Results: Sensitivity, specificity and accuracy of AFP in differentiate between HCC and cirrhosis. Sensitivity was (92%), specificity (90%) and accuracy (91%) with cut off value 5.8. Sensitivity, specificity and accuracy of H. EGF in differentiate between HCC and cirrhosis. Sensitivity was (99%), specificity (100%) and accuracy (99%) with cut off value 350. There was statistically substantial connection between AFP, H. EGF and other laboratory findings (P < 0.05).
Conclusion: In the detection of early HCC, epidermal growth factor as an indicator is a helpful biomarker that might supplement the effectiveness of AFP.